Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth E Powell

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
BMJ Open Gastroenterology|December 8, 2021
Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based studyAmy L Johnson, Isanka U Ratnasekera, Katharine M Irvine, et al.
BMJ Open Gastroenterology|February 11, 2021
Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AMKelly Lee Hayward, Amy L Johnson, Leigh U Horsfall, et al.
Journal of Gastroenterology and Hepatology|March 26, 2003
Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1Peter A Gochee, Julie R Jonsson, Andrew D Clouston, et al.
Hepatology (Baltimore, Md.)|March 29, 2005
Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosisAndrew D Clouston, Elizabeth E Powell, Meagan J Walsh, et al.
Patient Preference and Adherence|April 27, 2023
Low Prevalence of Use of Allied Health and Community Services for Patients with Cirrhosis in Australia: A Need for Greater EngagementElizabeth E Powell, Katherine A Stuart, Simon Finnigan, et al.
Scientific Reports|February 4, 2021
Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver diseaseKatharine M Irvine, Satomi Okano, Preya J Patel, et al.
Hepatology Communications|February 27, 2023
Higher levels of supportive care needs are linked to higher health service use and cost, poor quality of life, and high distress in patients with cirrhosis in Queensland, AustraliaPatricia C Valery, Katherine A Stuart, Christina M Bernardes, et al.
International Journal for Equity in Health|April 30, 2024
High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in AustraliaPatricia C Valery, Shruti Roche, Catherine Brown, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 23, 2024
Australians with metabolic dysfunction-associated steatotic liver disease have a twofold increase in the incidence of cancerElizabeth E Powell, Shruti Roche, Babak Sarraf, et al.
Journal of Hepatology|December 4, 2003
Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obeseJohn B Dixon, Prithi S Bhathal, Julie R Jonsson, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
BMJ Open Gastroenterology|December 8, 2021
Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based studyAmy L Johnson, Isanka U Ratnasekera, Katharine M Irvine, et al.
BMJ Open Gastroenterology|February 11, 2021
Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AMKelly Lee Hayward, Amy L Johnson, Leigh U Horsfall, et al.
Journal of Gastroenterology and Hepatology|March 26, 2003
Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1Peter A Gochee, Julie R Jonsson, Andrew D Clouston, et al.
Hepatology (Baltimore, Md.)|March 29, 2005
Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosisAndrew D Clouston, Elizabeth E Powell, Meagan J Walsh, et al.
Patient Preference and Adherence|April 27, 2023
Low Prevalence of Use of Allied Health and Community Services for Patients with Cirrhosis in Australia: A Need for Greater EngagementElizabeth E Powell, Katherine A Stuart, Simon Finnigan, et al.
Scientific Reports|February 4, 2021
Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver diseaseKatharine M Irvine, Satomi Okano, Preya J Patel, et al.
Hepatology Communications|February 27, 2023
Higher levels of supportive care needs are linked to higher health service use and cost, poor quality of life, and high distress in patients with cirrhosis in Queensland, AustraliaPatricia C Valery, Katherine A Stuart, Christina M Bernardes, et al.
International Journal for Equity in Health|April 30, 2024
High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in AustraliaPatricia C Valery, Shruti Roche, Catherine Brown, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 23, 2024
Australians with metabolic dysfunction-associated steatotic liver disease have a twofold increase in the incidence of cancerElizabeth E Powell, Shruti Roche, Babak Sarraf, et al.
Journal of Hepatology|December 4, 2003
Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obeseJohn B Dixon, Prithi S Bhathal, Julie R Jonsson, et al.
Pageof 12